All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
In October 2008, Phenomix Corp. seemed to be on top of the biotech world. After raising $165 million in venture capital to develop its Type II diabetes compound, dutogliptin, the San Diego start-up scored a development deal with Forest Laboratories Inc. potentially worth $340 million.